The FDA has approved lenacapavir (Yeztugo), a revolutionary HIV prevention drug boasting 99.9% efficacy with just two injections a year. While hailed as a medical breakthrough, its projected $25,000 annual cost could make it inaccessible to many. Experts warn that without affordable pricing and policy support, this life-saving innovation may remain out of reach for those most at risk.